Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

David R Muccino, Alyn H Morice, Surinder S Birring, Peter V Dicpinigaitis, Ian D Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A Smith

Research output: Contribution to journalArticlepeer-review

12 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough'. Together they form a unique fingerprint.

Medicine & Life Sciences